Drug – bio-affecting and body treating compositions – Nonspecific immunoeffector – per se ; or nonspecific... – Synthetic polymer or copolymer
Patent
1995-06-07
1999-02-16
Ketter, James
Drug, bio-affecting and body treating compositions
Nonspecific immunoeffector, per se ; or nonspecific...
Synthetic polymer or copolymer
530317, 514 27, 514183, A61K 4500, A61K 3813, C07K 512, C07D49106
Patent
active
058717536
ABSTRACT:
Methods and compositions are provided for modified cells, where a chimeric protein consisting of a ligand binding domain fused to an action domain is employed which initiates a signal which activates a biological process: transcription of at least one gene, usually a second construct introduced into the host cells; exocytosis; or an extracellular process. The second construct optimally present provides for a promoter which responds to a transcriptional activation action domain to provide for transcription, when an appropriate ligand binds to the ligand binding domain. Exemplary of the system is the use of an FKBP/CD3.zeta. or transcription factor fusion protein, using dimeric FK506 or FK520 as the ligand and a promoter responsive to NF-AT or other transcription factor requiring two molecules for transcriptional activation.
REFERENCES:
patent: 5120727 (1992-06-01), Kao et al.
patent: 5162333 (1992-11-01), Failli et al.
patent: 5171671 (1992-12-01), Evans et al.
Irving and Weiss, "The Cytoplasmic Domain of the T Cell Receptor .zeta. Chain is Sufficient to Couple to Receptor-Associated Signal Transduction Pathways"; Cell 64:891-901 (1991).
Kinet, "Antibody-Cell Interactions: Fc Receptors"; Cell 57:351-354 (1989).
Orloff et al., "Family of Disulphide-Linked Dimers Containing the .zeta. and .eta. Chains of the T-Cell Receptor and the .gamma. Chain of Fc Receptors"; Nature 347:189-191 (1990).
Durand et al., "Characterization of Antigen Receptor Response Elements Within the Interleukin-2 Enhancer"; Mol. Cell Biol. 8(2):1715-1724 (1988).
Letourneur and Klausner, Activation of T Cells by a Tyrosine Kinase Activation Domain in the Cytoplasmic Tail of CD3 .epsilon.; Science 255:79-82 (1992).
Flanagan et al., "Nuclear Association of a T-Cell Transcription Factor Blocked by FK-506 and Cyclosporin A"; Nature 352:803-807 (1991).
Byrn et al., "Biological Properties of a CD4 Immunoadhesin"; Nature 344:667-670 (1990).
Lanier et al., "Co-association of CD3.zeta. with a Receptor (CD16) for IgG Fc on Human Natural Killer Cells"; Nature 342:803-805 (1989).
Mattila et al., "The Actions of Cyclosporin A and FK506 Suggest a Novel Step in the Activation of T Lymphocytes"; EMBO J. 9(13):4425-4433 (1990).
Verweij et al., "Cell Type Specificity and Activation Requirements for NFAT-1 (Nuclear Factor of Activated T-Cells) Transcriptional Activity Determined by a New Method Using Transgenic Mice to Assay Transcriptional Activity of an Individual Nuclear Factor"; J. Biol. Chem. 265(26):15788-15795 (1990).
Clark et al., "The B Cell Antigen Receptor Complex: Association of Ig-.alpha. and IG-.beta. with Distinct Cytoplasmic Effectors"; Science 258:123-126 (1992).
Shaw et al., "Identification of a Putative Regulator of Early T Cell Activation Genes"; Science 241:202-205 (1988).
Weissman et al., "Molecular Cloning and Chromosomal Localization of the Human T-Cell Receptor .zeta. Chain: Distinction from the Molecular CD3 Complex"; Proc. Natl. Acad. Sci. USA 85:9709-9713 (1988).
Emmel et al., "Cyclosporin A Specifically Inhibits Function of Nuclear Proteins Involved in T-Cell Activation"; Science 246:1617-1620 (1989).
Eberle and Nuninger, "Synthesis of the Main Metabolite (OL-17) of Cyclosporin A"; J. Org. Chem. 57:2689-2691 (1992).
Traber et al., "Cyclosporins -New Analogues by Precursor Directed Biosynthesis"; J. Antibiotics 42:591-597 (1989).
Patchett et al., "Analogs of Cyclosporin A Modified at the D-ALA.sup.8 Position"; J. Antibiotics 45:94-102 (1992).
Donald et al., "C10 N-Acyl Modified FK-506: A Possible Hybrid Analogue of the Transition State of Peptidyl-Prolyl Cis-Trans Isomerization"; Tetrahedron Letters 31:1375-1378 (1991).
Nussbaumer et al., C9-Imino and C10-Amino Derivatives of Ascomycin (21-Ethyl-FK506); Tetrahedron Letters 33:3845-3846 (1992).
Evans et al., "Rhodium(I)-and Iridium(I)-Catalyzed Hydroboration Reactions: Scope and Synthetic Applications"; J. Am. Chem. Soc. 114:6671-6679 (1992).
Evans et al., "Mechanistic Study of the Rhodium(I)-Catalyzed Hydroboration Reaction"; J. Am. Chem. Soc. 114:6679-6685 (1992).
Ghosh et al., "N,N'-Disuccinimidyl Carbonate: A Useful Reagent for Alkoxycarbonylation of Amines"; Tetrahedron Letters 33:2781-2784 (1992).
Zelle et al., "A Systematic Degradation of Zincophorin: A Stereoselective Synthesis of the C.sub.17 -C.sub.25 Fragment"; J. Org. Chem. 51:5032-5036 (1986). Remarkably Chemoselective Reagent for the Reduction of Aldehydes in the Presence of Ketones"; J. Org. Chem. 46:4628-4629 (1981).
Fisher et al., "On the Remarkable Propensity for Carbon-Carbon Bond Cleavage Reactions in the C.sub.8 -C.sub.10 Region of FK-506"; J. Org. Chem. 56:2900-2907 (1991).
VanRheenen et al., "An Improved Catalytic OsO.sub.4 Oxidation of Olefins to Cis-1,2-Glycols Using Tertiary Amine Oxides as the Oxidant"; Tetrahedron Letters 23:1973-1976 (1976).
Fields, S. and Song, O., "A novel genetic system to detect protein-protein interactions"; Nature 340:245-246 (1989).
Schreiber, "Chemistry and Biology of the Immunophilins and Their Immuno-suppressive Ligands", Science 251:283-287 (1991).
Palmiter et al., "Transgenic Mice", Cell 41:343-345 (1985).
Itoh et al., "Effect of bcl-2 on Fas Antigen-Mediated Cell Death", Journal of Immunology 151:621-627 (1993).
Itoh and Nagata, "A Novel Protein Domain Required for Apoptosis", JBC 268:10932-10937 (1993).
Ptashne et al., "Activators and Targets", Nature 346:329-331 (1990).
Belshaw Peter
Crabtree Gerald R.
Ho Steffan
Schreiber Stuart L.
Spencer David M.
Berstein, Esq. David L.
Board of Trustees of the Leland Stanford Junior University
Clauss Isabelle M.
Ketter James
President and Fellows of Harvard College
LandOfFree
Regulated transcription of targeted genes and other biological e does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Regulated transcription of targeted genes and other biological e, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Regulated transcription of targeted genes and other biological e will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2059747